Logiscreen

Cytosorbents Corp

$0.48
Market Cap 29.91M
ROE -165.1%
Gross Margin 69.2%
Debt/Equity 13.1
Current Ratio 1.1
Revenue QoQ 1.6%
EPS QoQ 3.0%
F-Score 3

About

CytoSorbents Corporation, formerly MedaSorb Technologies Corporation is a development-stage therapeutic medical device company. As of December 31, 2011, the Company had developed and focuses on commercializing a blood purification technology that would be able to remove middle molecular weight toxins from circulating blood and physiologic fluids. The Company has developed two products, CytoSorb and BetaSorb utilizing its adsorbent polymer technology. These products are known medically as hemoperfusion devices. As of December 31, 2011, the Company had initiated and opened for enrollment a total of 14 hospital units to participate in its clinical study. The CytoSorb device consists of a cartridge containing adsorbent polymer beads, that are intended to remove toxins and other substances from blood and physiologic fluids. The cartridge incorporates connectors at either end of the device, which connect directly to an extra-corporeal circuit (bloodlines) on a stand alone basis.

Exchange
NASDAQ
Sector
Healthcare
Industry
Medical Devices

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-2.12
vs median 35.63
P/B
11.43
vs median 2.25
ROE
-1.65
vs median 0.09

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics